Anmeldung erfolgt in Kürze...
Details werden geladen...
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions
Ähnliche Seiten
An ASCO preview: What to watch for at cancer research's big meeting | STAT
https://www.statnews.com/2026/05/28/asco-preview-cancer-meeting/BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
https://www.statnews.com/2026/05/30/asco-news-day-2-biontech-pfizer-kelun-merck-pazdur/
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
https://www.finanznachrichten.de/nachrichten-2026-05/68638430-immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-developme-399.htm
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/ascentage-pharma-releases-latest-clinical-data-from-multiple-trials-at-asco-2026/2349756Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/asher-biotherapeutics-announces-two-presentations-at-the-asco-2026-annual-meeting-highlighting-clinical-progress-across-its-cd8-targeted-cytokine-pipeline/2349690